The NABIP expressed frustration at CMS’ statement for placing blame on brokers and agents and not acknowledging evidence that switches were made by automated programs.
The National Association of Benefits and Insurance Professionals (NABIP) responded to a recent statement from the Centers for Medicare & Medicaid Services (CMS) that focused on the issue of unauthorized policy and plan changes on the ACA Marketplace.1 The statement from CMS came in response to reports that users’ plans had been changed without their knowledge or permission. The new plans did not always include the patients’ doctors or required prescriptions.
In a press release, NABIP CEO Jessica Brooks-Woods said, “We are deeply troubled by the portrayal of health insurance agents and brokers in the CMS statement. What was not addressed is the possibility that a large number of these unauthorized plan switches are due to technological vulnerabilities that allow automated systems to make the switches, not the unethical practices of agents and brokers."
According to CMS’ statement, it received an estimated 40,000 complaints of unauthorized plan switches in the first three months of 2024.2 CMS states that it is working to terminate brokers who defraud consumers and is looking into taking stronger actions against brokers and agents who are involved in unauthorized switches.
Brooks-Woods believes that these switches are not the result of individual brokers or agents. "We have presented evidence of systems switching thousands of consumers within mere minutes—a task impossible for humans. This clearly indicates a need for enhanced security protocols within the systems used by CMS," Brooks-Woods said.
She continued, "One of our members lost several thousand clients in less than three minutes due to these vulnerabilities. These incidents not only represents a significant revenue loss but also disrupts the trust and relationship established with healthcare consumers."
Eric Kohlsdorf, president of the NABIP, shared in Brooks-Woods frustration, saying, “As a broker committed to helping consumers access affordable insurance while adhering to extensive government regulations, it's frustrating for our profession to be blamed. NABIP members adhere to a strict ethical code designed to support, protect, and advocate for Americans and our industry. NABIP is eager to collaborate with all stakeholders to find solutions and protections that Americans deserve."
In March of this year, the NABIP launched a campaign promoting its Healthcare Bill of Rights.3 This program outlines the organization’s view on what rights each American citizen should have when it comes to healthcare.
In a press release issued at the time, Brooks-Woods said, “NABIP's Healthcare Bill of Rights articulates the core values and principles of the association. They represent not just our beliefs but NABIP's commitment to ensuring that every American is empowered with the right to high-quality, affordable healthcare. These rights stand as the pillars by which we define our mission, measure our progress, and drive toward a future where equitable healthcare is not a privilege but a standard for all. The announcement of NABIP's Healthcare Bill of Rights took place at our recent Capitol Conference, showcasing NABIP's dedication to shaping a healthcare system that prioritizes the well-being and rights of all Americans. This significant milestone is a cornerstone in our commitment to creating a healthcare landscape that is privately accessible and affordable for every citizen."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
2 Commerce Drive
Cranbury, NJ 08512